Compare Lithium Americas Corp (LAC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Neurocrine Biosciences Inc — how do they compare? Lithium Americas Corp trades at $3.26 (market cap $1.18B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 14.2× Lithium Americas Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| LAC | NBIX | |
|---|---|---|
Market Cap | $1.18B | $16.76B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $185.50 |
52-Week Low | $2.71 | $123.10 |
Enterprise Value | $1.30B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.23, up 6.95% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $122.09 million for 2025 and continues to burn cash from operations. Recent news highlights $175 million financing for Thacker Pass construction, providing balance sheet support amid ongoing capital expenditures exceeding $900 million annually.
While analyst consensus leans positive with no sell ratings, significant execution risks persist as LAC navigates peak construction phase. The stock faces headwinds from negative ROE (-11.35%) and cash burn, though strategic positioning in lithium development offers long-term potential if project timelines and funding are successfully managed.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
